<html><body><span><table class="info"><tr><th nowrap="">ClinicalTrials Identifier:</th><td>NCT00000193</td></tr><tr><th>Updated:</th><td>2005_06_</span><del style="background:#ffe6e6;">2</del><span>3</span><ins style="background:#e6ffe6;">0</ins><span></td></tr><tr><th class="section" colspan="2"><h2>Descriptive Information</h2></th></tr><tr><th>Brief title</th><td><p>Neurobiology of Opioid Dependence: 2 - 2</p></td></tr><tr><th>Official title</th><td><p>Neurobiology of Opioid Dependence: 2</p></td></tr><tr><th>Brief summary</th></tr><tr><td class="bigdent" colspan="2"><p>The purpose of this study is to evaluate the effects of gamma hydroxybutyric on naloxone-precipitated opiate withdrawal.</p></td></tr><tr><th>Detailed description</th></tr><tr><td class="bigdent" colspan="2"><p></p></td></tr><tr><th>Phase</th><td>Phase 2</td></tr><tr><th>Study type</th><td>Interventional</td></tr><tr><th>Study design</th><td>Treatment</td></tr><tr><th>Study design</th><td>Double Blind</td></tr><tr><th>Study design</th><td>Placebo Control</td></tr><tr><th>Primary outcome</th><td>Measure:          Behavioral, subjective, measures of naloxone-preci      </td></tr><tr><th>Primary outcome</th><td>Measure:          Phsyiological, neuroendocrine measures of naloxone      </td></tr><tr><th>Condition</th><td>         Opioid-Related Disorders      </td></tr><tr><th>Intervention</th><td><div>Drug: Gamma hydroxybutyric</div></td></tr><tr><th>Reference</th><td><div>Citation: Neuropsychopharmacology, 1996; 14(3) pp 187-193. Neruopsychopharmacology 1996; 14(3), 187-193</div><div>MEDLINE: </div></td></tr><tr><th class="section" colspan="2"><h2>Recruitment Information</h2></th></tr><tr><th>Status</th><td>            Completed         </td></tr><tr><th>Start date</th><td>         1996-01      </td></tr><tr><th>Last data entry date</th><td>         1996-10      </td></tr><tr><th>Criteria</th></tr><tr><td class="bigdent" colspan="2"><p>Please contact site for information.</p></td></tr><tr><th>Gender</th><td>            Male         </td></tr><tr><th>Minimum age</th><td>N/A</td></tr><tr><th>Maximum age</th><td>N/A</td></tr><tr><th>Healthy volunteers</th><td>No</td></tr><tr><th>Expected enrollment</th><td>0</td></tr><tr><th class="section" colspan="2"><h2>Administrative Data</h2></th></tr><tr><th>Organization name</th><td>National Institute on Drug Abuse (NIDA)</td></tr><tr><th>Organization study ID</th><td>NIDA-00191-2</td></tr><tr><th>Secondary ID</th><td>            K20-00191-2         </td></tr><tr><th>Sponsor</th><td>               National Institute on Drug Abuse (NIDA)            </td></tr><tr><th>Collaborator</th><td>               Yale University            </td></tr><tr><th>Health Authority</th><td>               United States: Federal Government         </td></tr></table></span></body></html>